Mania Ackermann, Henning Kempf, Miriam Hetzel, Christina Hesse, Anna Rafiei Hashtchin, Kerstin Brinkert, Juliane Wilhelmine Schott, Kathrin Haake, Mark Philipp Kühnel, Silke Glage, Constanca Figueiredo, Danny Jonigk, Katherina Sewald, Axel Schambach, Sabine Wronski, Thomas Moritz, Ulrich Martin, Robert Zweigerdt, Antje Munder, Nico Lachmann
The increasing number of severe infections with multi-drug-resistant pathogens worldwide highlights the need for alternative treatment options. Given the pivotal role of phagocytes and especially alveolar macrophages in pulmonary immunity, we introduce a new, cell-based treatment strategy to target bacterial airway infections. Here we show that the mass production of therapeutic phagocytes from induced pluripotent stem cells (iPSC) in industry-compatible, stirred-tank bioreactors is feasible. Bioreactor-derived iPSC-macrophages (iPSC-Mac) represent a highly pure population of CD45+ CD11b+ CD14+ CD163+ cells, and share important phenotypic, functional and transcriptional hallmarks with professional phagocytes, however with a distinct transcriptome signature similar to primitive macrophages...
November 30, 2018: Nature Communications